Differences in abuse potential of ADHD drugs measured by contrasting poison centre and therapeutic use data
Louise Schow Jensen1, Anne Katrine Pagsberg, Kim Peder Dalhoff
1Department of Clinical Pharmacology, Bispebjerg University Hospital , Copenhagen , Denmark.
Context:
Atomoxetine (ATX) is the treatment of choice for attention deficit hyperactivity disorders with co-morbid risk of drug abuse, although its abuse potential needs to be qualified. The purpose of this study is to analyse ATX misuse in relation to therapeutic use and compare our results with that of methylphenidate (MPH).
Methods And Materials:
Data on enquiries were extracted from the Danish Poison Information Centre database (January 2006 to June 2012), while data on therapeutic use were provided by the Danish State Serum Institute (2007-2011).
Results:
The study included 28 ATX and 394 MPH enquiries. Frequency of ATX enquiries did not show a significant correlation to either sale or number of treated patients but for MPH, both correlations were significant (p = 0.001 and p = 0.0008, respectively). The enquiries/number of treated patients relationship differed significantly between ATX and MPH (p = 0.018), but not the enquiries/sale relationship. The proportion of exposures motivated by recreational drug use was significantly lower for ATX (19%) than that for MPH (40%) (p = 0.038).
Discussion And Conclusion:
These results suggest that ATX is used by adults for non-medical purposes including recreational use, but to a lesser extent than MPH.
More Related Videos
Related Concept Videos
Drug Toxicity: Risk factors
Drug Toxicity: Overview
Pharmaceutical Poisoning: Potential Scenarios
Drug Toxicity: Dose-Dependent Reactions
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...


